Get the Stockscreener App
2.67
2.55%
-0.07
After Hours:
2.68
0.01
+0.37%
Acumen Pharmaceuticals Inc stock is traded at $2.67, with a volume of 225.14K.
It is down -2.55% in the last 24 hours and up +24.19% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
See More
Previous Close:
$2.74
Open:
$2.74
24h Volume:
225.14K
Relative Volume:
0.48
Market Cap:
$192.85M
Revenue:
-
Net Income/Loss:
$-113.28M
P/E Ratio:
-1.4388
EPS:
-1.8557
Net Cash Flow:
$-105.55M
1W Performance:
-3.61%
1M Performance:
+24.19%
6M Performance:
+36.22%
1Y Performance:
+130.17%
1-Day Range:
$2.66
$2.78
1-Week Range:
$2.50
$2.83
52-Week Range:
$1.14
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.67 | 192.85M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals, Inc. commits to advancing targeted therapies for Alzheimer care - Traders Union
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Index - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Value Benchmark - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Acumen Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ABOS) - TradingView
ABOS Forecast — Price Target — Prediction for 2027 - TradingView
Acumen Pharmaceuticals Inc (ABOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - BioSpace
Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acumen Pharmaceuticals Insider Makes Eye-Catching Stock Move - TipRanks
Acumen Pharmaceuticals director Porter sells $75,239 in stock - Investing.com UK
Acumen Pharmaceuticals director Porter sells $75,239 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Inc (ABOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acumen Pharmaceuticals Inc - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options - Stock Titan
Acumen exercises option for JCR brain technology - grafa.com
Acumen Pharmaceuticals Inc (ABOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Institutional Confidence - TradingKey
Director to sell 13,040 shares (NASDAQ: ABOS) in stock option exercise - Stock Titan
Acumen selects development candidates for Alzheimer’s disease - BioWorld News
Acumen nominates two Alzheimer’s candidates for development - Investing.com UK
Acumen nominates two Alzheimer’s candidates for development By Investing.com - Investing.com South Africa
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease - Yahoo Finance
ABOS (NASDAQ: ABOS) Form 144 shows proposed sale of 12,800 shares - Stock Titan
Acumen Pharmaceuticals, Inc. advances two new Enhanced Brain Delivery candidates for Alzheimer treatment - Traders Union
Acumen Advances Enhanced Brain Delivery Alzheimer’s Drug Candidates - TipRanks
Acumen Pharmaceuticals nominates two EBD candidates, targets mid-2027 IND with 14-40x brain penetration in NHPs - TradingView
Acumen Pharmaceuticals Nominates Two Development Candidates in Enhanced Brain Delivery Program for Alzheimer's Disease Treatment - Quiver Quantitative
Acumen (NASDAQ: ABOS) advances two EBD Alzheimer’s drug candidates - Stock Titan
Two new antibody designs aim for higher brain delivery in Alzheimer’s - Stock Titan
[144] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen Pharmaceuticals Q1 earnings call highlights - MSN
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Acumen Pharmaceuticals director sells $14,272 in company stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals director sells $14,272 in company stock - Investing.com
Insider Sell: Nathan Fountain Sells 6,400 Shares of Acumen Pharm - GuruFocus
Acumen Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Fountain Nathan B - Moomoo
Director Nathan Fountain sells 6,400 Acumen (ABOS) shares at ~$2.23 - Stock Titan
Acumen Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
ABOS Q1 2026 Earnings: Narrower-than-Expected Loss as Phase 2 Readout ApproachesDownward Estimate Revision - newsline.com
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) director receives RSU and option grants - Stock Titan
Acumen (NASDAQ: ABOS) director granted RSUs and options vesting by 2027 - Stock Titan
Acumen Pharmaceuticals (ABOS) director receives new RSU and option awards - Stock Titan
Acumen Pharmaceuticals (ABOS) grants RSUs and stock options to director - Stock Titan
Acumen Pharmaceuticals (ABOS) director receives RSU and option grants - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) director awarded RSUs and options - Stock Titan
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Porter Derrell | Director |
Jun 15 '26 |
Option Exercise |
1.07 |
6,460 |
6,912 |
54,760 |
| Porter Derrell | Director |
Jun 17 '26 |
Sale |
2.33 |
13,040 |
30,318 |
35,500 |
| Porter Derrell | Director |
Jun 16 '26 |
Sale |
2.33 |
12,800 |
29,773 |
35,500 |
| Porter Derrell | Director |
Jun 15 '26 |
Sale |
2.35 |
6,460 |
15,149 |
48,300 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):